Literature DB >> 23064233

Tumor stroma as targets for cancer therapy.

Jing Zhang1, Jinsong Liu.   

Abstract

Cancer is not only composed malignant epithelial component but also stromal components such as fibroblasts, endothelial cells, and inflammatory cells, by which an appropriate tumor microenvironment (TME) is formed to promote tumorigenesis, progression, and metastasis. As the most abundant component in the TME, cancer-associated fibroblasts (CAFs) are involved in multifaceted mechanistic details including remodeling the extracellular matrix, suppressing immune responses, and secreting growth factors and cytokines that mediate signaling pathways to extensively affect tumor cell growth and invasiveness, differentiation, angiogenesis, and chronic inflammatory milieu. Today, more and more therapeutic strategies are purposefully designed to target the TME as well as tumor cells. This review will focus on the role of CAFs in tumor development and the novel strategies to target this component to inhibit the tumor growth.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064233      PMCID: PMC3556178          DOI: 10.1016/j.pharmthera.2012.10.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  202 in total

1.  Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.

Authors:  Sichao Huang; Rui Fang; Jun Xu; Shenghong Qiu; Huan Zhang; Jun Du; Shaohui Cai
Journal:  J Drug Target       Date:  2011-02-02       Impact factor: 5.121

Review 2.  COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention.

Authors:  Mary-Clare Cathcart; Kenneth J O'Byrne; John V Reynolds; Jacintha O'Sullivan; Graham P Pidgeon
Journal:  Biochim Biophys Acta       Date:  2011-10-01

3.  MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions.

Authors:  Christian F Singer; Nicole Kronsteiner; Erika Marton; Marion Kubista; Kevin J Cullen; Kora Hirtenlehner; Michael Seifert; Ernst Kubista
Journal:  Breast Cancer Res Treat       Date:  2002-03       Impact factor: 4.872

4.  Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation.

Authors:  Jonas Fuxe; Sébastien Tabruyn; Katharine Colton; Harras Zaid; Alicia Adams; Peter Baluk; Erin Lashnits; Tohru Morisada; Tom Le; Shaun O'Brien; David M Epstein; Gou Young Koh; Donald M McDonald
Journal:  Am J Pathol       Date:  2011-05-06       Impact factor: 4.307

5.  Antiangiogenic therapy: creating a unique "window" of opportunity.

Authors:  Michelle I Lin; William C Sessa
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

Review 6.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

7.  CXCR4 regulates growth of both primary and metastatic breast cancer.

Authors:  Matthew C P Smith; Kathryn E Luker; Joel R Garbow; Julie L Prior; Erin Jackson; David Piwnica-Worms; Gary D Luker
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

8.  Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.

Authors:  F van Zijl; M Mair; A Csiszar; D Schneller; G Zulehner; H Huber; R Eferl; H Beug; H Dolznig; W Mikulits
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Regulation of basic fibroblast growth factor expression by transforming growth factor beta in cultured human prostate stromal cells.

Authors:  M T Story; K A Hopp; D A Meier
Journal:  Prostate       Date:  1996-04       Impact factor: 4.104

View more
  59 in total

1.  Microenvironmental interactions and expression of molecular markers associated with epithelial-to-mesenchymal transition in colorectal carcinoma.

Authors:  Sun-Jae Lee; Chun-Seok Yang; Dae-Dong Kim; Yu-Na Kang; Sang Gyu Kwak; Jae-Bok Park; Chang-Ho Cho; Kwan-Kyu Park
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 2.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

3.  Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells.

Authors:  Tania Fiaschi; Elisa Giannoni; Maria Letizia Taddei; Paolo Cirri; Alberto Marini; Gianfranco Pintus; Cristina Nativi; Barbara Richichi; Andrea Scozzafava; Fabrizio Carta; Eugenio Torre; Claudiu T Supuran; Paola Chiarugi
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

4.  Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.

Authors:  Jing Zhang; Lei Miao; Shutao Guo; Yuan Zhang; Lu Zhang; Andrew Satterlee; William Y Kim; Leaf Huang
Journal:  J Control Release       Date:  2014-03-15       Impact factor: 9.776

5.  Novel approaches for quantifying protein biomarkers in gliomas: benefits and pitfalls.

Authors:  Rikke H Dahlrot; Mia D Sørensen; Ann Mari Rosager; Sofie Hellwege; Julie A Bangsø; Tine Rosenberg; Stine A Petterson; Jacob Klitkou; Sigurd Fosmark; Steinbjørn Hansen; Bjarne W Kristensen
Journal:  CNS Oncol       Date:  2014-07

Review 6.  Developments in preclinical cancer imaging: innovating the discovery of therapeutics.

Authors:  James R W Conway; Neil O Carragher; Paul Timpson
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

7.  Deficient expression of aldehyde dehydrogenase 1A1 is consistent with increased sensitivity of Gorlin syndrome patients to radiation carcinogenesis.

Authors:  Aaron T Wright; Thierry Magnaldo; Ryan L Sontag; Lindsey N Anderson; Natalie C Sadler; Paul D Piehowski; Yannick Gache; Thomas J Weber
Journal:  Mol Carcinog       Date:  2013-11-27       Impact factor: 4.784

Review 8.  Naturally occurring compounds acting as potent anti-metastatic agents and their suppressing effects on Hedgehog and WNT/β-catenin signalling pathways.

Authors:  L Farahmand; B Darvishi; K Majidzadeh-A; A Madjid Ansari
Journal:  Cell Prolif       Date:  2016-09-27       Impact factor: 6.831

9.  Recent Advances in Head and Neck Tumor Microenvironment-Based Therapy.

Authors:  Muzafar A Macha; Nissar A Wani; Rais A Ganai; Ajaz A Bhat; Abid Hamid; Sheema Hashem; Mohammad Haris; Sham S Chauhan; Mohammad A Zargar; Surinder K Batra
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  C-C chemokine receptor 5 on pulmonary mesenchymal cells promotes experimental metastasis via the induction of erythroid differentiation regulator 1.

Authors:  Robert L Mango; Qing Ping Wu; Michelle West; Everett C McCook; Jonathan S Serody; Hendrik W van Deventer
Journal:  Mol Cancer Res       Date:  2013-11-06       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.